Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer,Expert Review of Pharmacoeconomics & Outcomes Research

当前位置： X-MOL 学术 › Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 2.3 ) Pub Date : 2024-02-28 , DOI: 10.1080/14737167.2024.2319605
Shih Ping Lai, Shyh-Yau Wang, Agnes LF Chan, John Hang Leung, Hei-Tung Yip

The cost-effectiveness of adding bevacizumab biosimilar with or without chemotherapy (CT) and drug wastage in treating platinum-resistant recurrent ovarian cancer (PRrOC) was assessed.A three-state...

中文翻译：